Research today. Impact tomorrow.

25% Off the entire catalogue →

Same standards. Greater possibilities.

Research Use Only18+Not for Human ConsumptionReconstitution Materials Not Supplied
Peptide Database

Metabolic & GLP-1 research

Semaglutide (Ozempic): Research, Mechanism & Current Evidence

GLP-1 receptor agonist approved for type 2 diabetes and weight management; the most studied compound in its class.

Also known as Ozempic · Wegovy · Rybelsus · GLP-1 receptor agonist

Research use onlyStrongest evidence: controlled clinical trialReviewed
DatabaseReferences

What is Semaglutide?

Semaglutide is a long-acting imitation of GLP-1, a hormone the gut releases after eating. Developed by Novo Nordisk, it is sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management.

It is the most extensively studied compound in this category, with trial programmes running to tens of thousands of participants and several years of follow-up.

Status: Approved for type 2 diabetes and weight management in the UK, US and EU.

What is Semaglutide researched for?

The SUSTAIN programme studied blood sugar control, STEP studied body weight, and SELECT studied cardiovascular outcomes in people with overweight or obesity and existing heart disease but without diabetes.

Later work has looked at kidney outcomes, fatty liver disease and knee osteoarthritis pain associated with obesity.

  • FDA-approved for chronic weight management with average 15-20% body weight loss in clinical trials.
  • Reduces hunger and food cravings through central nervous system GLP-1 receptor activation.
  • Long-term studies show maintained weight loss with continued treatment over 2+ years.
  • FDA-approved for type 2 diabetes with HbA1c reductions of 1.5-2% in clinical trials.
  • Proven 26% reduction in cardiovascular death, MI, or stroke in high-risk diabetes patients.
  • Improves insulin secretion and may preserve pancreatic beta cell function.
  • Addresses multiple components: weight, glucose, blood pressure, and lipids.
  • Emerging evidence for improvements in non-alcoholic fatty liver disease.
  • Decreases systemic inflammation markers independent of weight loss.

How does Semaglutide work?

Semaglutide activates the GLP-1 receptor. In plain terms it extends and amplifies the signal your body normally sends after a meal: the stomach empties more slowly, the pancreas releases insulin more readily when blood sugar is high, and appetite centres in the brain register fullness sooner.

Because the insulin effect depends on blood sugar already being elevated, the risk of blood sugar dropping too low is lower than with insulin itself.

Reported targets: GLP-1 receptor

What does the research show?

STEP-1, published in 2021, reported roughly 15% average weight loss at 68 weeks on 2.4mg weekly. SELECT, published in 2023, reported a reduction in major cardiovascular events in people with existing cardiovascular disease and overweight or obesity — the first outcome trial of its kind in this class.

Gastrointestinal effects are the most commonly reported problem. Discontinuation for side effects in the large trials was in the single-digit percentages.

Limitations of the current evidence

Weight regain after stopping has been documented in extension studies, which is central to how the compound is understood rather than a footnote.

Trials enrol supervised populations with regular contact and dose adjustment, so results in other settings are not guaranteed to match.

References

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Wilding JPH, Batterham RL, Calanna S, et al. · The New England journal of medicine · 2021

    14.9% average weight loss vs 2.4% placebo over 68 weeks with 2.4mg weekly. 86% achieved ≥5% weight loss; 51-64% achieved ≥15% weight loss.

    PMID 33567185

  2. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · The New England journal of medicine · 2023

    20% reduction in MACE (CV death, MI, or stroke) with semaglutide 2.4mg vs placebo over mean 40 months. First GLP-1 RA to demonstrate cardiovascular benefit in non-diabetic population.

    PMID 37952131

  3. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    Marso SP, Bain SC, Consoli A, et al. · The New England journal of medicine · 2016

    26% reduction in MACE (HR 0.74) with semaglutide vs placebo. Established cardiovascular safety and benefit profile for semaglutide in type 2 diabetes.

    Early human study · PMID 27633186

  4. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5)

    Garvey, W.T., et al. · Nature Medicine · 2022

    Sustained weight loss of 15.2% at week 104 vs 2.6% placebo. 77.1% achieved ≥5% weight loss at 2 years, demonstrating long-term efficacy.

  5. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    Husain M, Birkenfeld AL, Donsmark M, et al. · The New England journal of medicine · 2019

    Oral semaglutide was noninferior to placebo for cardiovascular safety. Numerically fewer CV deaths in oral semaglutide group (0.9% vs 1.9%).

    Early human study · PMID 31185157

  6. Once-Weekly Semaglutide in Adolescents with Obesity

    Weghuber D, Barrett T, Barrientos-Pérez M, et al. · The New England journal of medicine · 2022

    16.1% BMI reduction with semaglutide vs 0.6% increase with placebo over 68 weeks. 44.9% of semaglutide recipients reclassified to normal-weight or overweight BMI category.

    PMID 36322838

  7. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

    Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. · The New England journal of medicine · 2023

    Semaglutide 2.4mg reduced symptoms, physical limitations, and improved exercise function in obesity-related HFpEF. Reduced inflammation and appeared to improve adverse cardiac remodeling.

    Early human study · PMID 37622681

  8. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

    Perkovic V, Tuttle KR, Rossing P, et al. · The New England journal of medicine · 2024

    24% lower risk of primary kidney outcome (kidney failure, sustained eGFR decline, or renal/CV death) with semaglutide vs placebo. 29% reduction in CV death. Trial stopped early for efficacy.

    Early human study · PMID 38785209

  9. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

    Sanyal AJ, Newsome PN, Kliers I, et al. · The New England journal of medicine · 2025

    62.9% achieved MASH resolution without fibrosis worsening vs 34.3% placebo at 72 weeks. Combined resolution and fibrosis improvement in 32.7% vs 16.1% placebo. Mean weight loss of 10.5%.

    Controlled clinical trial · PMID 40305708

  10. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

    Garvey WT, Batterham RL, Bhatta M, et al. · Nature medicine · 2022

    PMID 36216945

Common questions

Why does semaglutide help heart disease even without diabetes?

The SELECT trial (17,604 people) proved semaglutide reduces cardiovascular events by 20% in obese people without diabetes. The mechanism involves inflammation reduction, improved lipid profiles, blood pressure lowering, and hepatic fat reduction—benefits that protect the heart independent of glucose control.

Is semaglutide's weight loss real fat loss or mostly water/muscle?

Mostly real fat loss. Clinical trials show semaglutide reduces fat mass substantially with lean mass preservation (similar ratio to other weight loss treatments). The 15-20% weight loss isn't just water—it's sustained fat reduction. However, some lean mass loss does occur, which is why resistance training is recommended.